Association of Intraindividual Difference in Estimated Glomerular Filtration Rate by Creatinine vs Cystatin C and End-stage Kidney Disease and Mortality
IMPORTANCE: As cystatin C is increasingly adopted to estimate glomerular filtration rate (eGFR), clinicians will encounter patients in whom cystatin C-based eGFR (eGFRcys) and creatinine-based eGFR (eGFRcr) differ widely. The clinical implications of these differences, eGFRdiffcys-cr, are unknown. O...
Saved in:
| Published in: | JAMA Network Open Vol. 5; no. 2; p. e2148940 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
American Medical Association
01.02.2022
|
| Subjects: | |
| ISSN: | 2574-3805, 2574-3805 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | IMPORTANCE: As cystatin C is increasingly adopted to estimate glomerular filtration rate (eGFR), clinicians will encounter patients in whom cystatin C-based eGFR (eGFRcys) and creatinine-based eGFR (eGFRcr) differ widely. The clinical implications of these differences, eGFRdiffcys-cr, are unknown. OBJECTIVE: To evaluate the associations of eGFRdiffcys-cr with end-stage kidney disease (ESKD) and mortality among individuals with chronic kidney disease (CKD). DESIGN, SETTING, AND PARTICIPANTS: This is a prospective cohort study of 4956 individuals with mild to moderate CKD from 7 clinical centers in the United States who enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study between 2003 to 2018. Statistical analyses were completed in December 2021. EXPOSURES: eGFRdiffcys-cr (eGFRcys − eGFRcr) was calculated at baseline and annually thereafter for 3 years. Because 15 mL/min/1.73 m2 represents a clinically meaningful difference in eGFR that also distinguishes CKD stages, eGFRdiffcys-cr was categorized as: less than −15 mL/min/1.73 m2, −15 to 15 mL/min/1.73 m2, and 15 mL/min/1.73 m2 or greater. MAIN OUTCOMES AND MEASURES: The outcomes of ESKD, defined as initiation of maintenance dialysis or receipt of a kidney transplant, and all-cause mortality were adjudicated from study entry until administrative censoring in 2018. RESULTS: Among 4956 participants with mean (SD) age of 59.5 (10.5) years, 2152 (43.4%) were Black, 515 (10.4%) were Hispanic, and 2113 (42.6%) were White. There were 2156 (43.5%) women and 2800 (56.5%) men. At baseline, eGFRcys and eGFRcr values differed by more than 15 mL/min/1.73 m2 in one-third of participants (1638 participants [33.1%]). Compared with participants with similar baseline eGFRcys and eGFRcr (eGFRdiffcys-cr −15 to 15 mL/min/1.73 m2), those in whom eGFRcys was substantially lower than eGFRcr (eGFRdiffcys-cr < −15 mL/min/1.73 m2) had a higher risk of mortality (hazard ratio [HR], 1.86; 95% CI, 1.40-2.48) while those with eGFRdiffcys-cr of 15 mL/min/1.73 m2 or greater had lower risks of ESKD (subHR [SHR], 0.73; 95% CI, 0.59-0.89) and mortality (HR, 0.68; 95% CI, CI 0.58-0.81). In time-updated analyses, participants with eGFRdiffcys-cr less than −15 mL/min/1.73 m2 had higher risks of ESKD (SHR, 1.83; 95% CI, 1.10-3.04) and mortality (HR, 3.03; 95% CI, 2.19-4.19) compared with participants with similar eGFRcys and eGFRcr. Conversely, participants with eGFRdiffcys-cr of 15 mL/min/1.73 m2 or greater had lower risks of ESKD (SHR, 0.50; 95% CI, 0.35-0.71) and mortality (HR, 0.58; 95% CI, 0.45-0.75). Longitudinal changes in eGFRdiffcys-cr were associated with mortality risk. Compared with participants who had similar slopes by eGFRcys and eGFRcr, those with smaller eGFRcr declines had an 8-fold increased mortality risk (HR, 8.20; 95% CI, 6.37-10.56), and those with larger apparent declines by eGFRcr had a lower mortality risk (HR, 0.14; 95% CI, 0.08-0.24). CONCLUSIONS AND RELEVANCE: These findings suggest that large differences between eGFRcys and eGFRcr were common in persons with CKD. These differences and their changes over time may be informative of ESKD and mortality risks, warranting monitoring of both eGFRcys and eGFRcr in this high-risk population. |
|---|---|
| AbstractList | As cystatin C is increasingly adopted to estimate glomerular filtration rate (eGFR), clinicians will encounter patients in whom cystatin C-based eGFR (eGFRcys) and creatinine-based eGFR (eGFRcr) differ widely. The clinical implications of these differences, eGFRdiffcys-cr, are unknown.ImportanceAs cystatin C is increasingly adopted to estimate glomerular filtration rate (eGFR), clinicians will encounter patients in whom cystatin C-based eGFR (eGFRcys) and creatinine-based eGFR (eGFRcr) differ widely. The clinical implications of these differences, eGFRdiffcys-cr, are unknown.To evaluate the associations of eGFRdiffcys-cr with end-stage kidney disease (ESKD) and mortality among individuals with chronic kidney disease (CKD).ObjectiveTo evaluate the associations of eGFRdiffcys-cr with end-stage kidney disease (ESKD) and mortality among individuals with chronic kidney disease (CKD).This is a prospective cohort study of 4956 individuals with mild to moderate CKD from 7 clinical centers in the United States who enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study between 2003 to 2018. Statistical analyses were completed in December 2021.Design, Setting, and ParticipantsThis is a prospective cohort study of 4956 individuals with mild to moderate CKD from 7 clinical centers in the United States who enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study between 2003 to 2018. Statistical analyses were completed in December 2021.eGFRdiffcys-cr (eGFRcys - eGFRcr) was calculated at baseline and annually thereafter for 3 years. Because 15 mL/min/1.73 m2 represents a clinically meaningful difference in eGFR that also distinguishes CKD stages, eGFRdiffcys-cr was categorized as: less than -15 mL/min/1.73 m2, -15 to 15 mL/min/1.73 m2, and 15 mL/min/1.73 m2 or greater.ExposureseGFRdiffcys-cr (eGFRcys - eGFRcr) was calculated at baseline and annually thereafter for 3 years. Because 15 mL/min/1.73 m2 represents a clinically meaningful difference in eGFR that also distinguishes CKD stages, eGFRdiffcys-cr was categorized as: less than -15 mL/min/1.73 m2, -15 to 15 mL/min/1.73 m2, and 15 mL/min/1.73 m2 or greater.The outcomes of ESKD, defined as initiation of maintenance dialysis or receipt of a kidney transplant, and all-cause mortality were adjudicated from study entry until administrative censoring in 2018.Main Outcomes and MeasuresThe outcomes of ESKD, defined as initiation of maintenance dialysis or receipt of a kidney transplant, and all-cause mortality were adjudicated from study entry until administrative censoring in 2018.Among 4956 participants with mean (SD) age of 59.5 (10.5) years, 2152 (43.4%) were Black, 515 (10.4%) were Hispanic, and 2113 (42.6%) were White. There were 2156 (43.5%) women and 2800 (56.5%) men. At baseline, eGFRcys and eGFRcr values differed by more than 15 mL/min/1.73 m2 in one-third of participants (1638 participants [33.1%]). Compared with participants with similar baseline eGFRcys and eGFRcr (eGFRdiffcys-cr -15 to 15 mL/min/1.73 m2), those in whom eGFRcys was substantially lower than eGFRcr (eGFRdiffcys-cr < -15 mL/min/1.73 m2) had a higher risk of mortality (hazard ratio [HR], 1.86; 95% CI, 1.40-2.48) while those with eGFRdiffcys-cr of 15 mL/min/1.73 m2 or greater had lower risks of ESKD (subHR [SHR], 0.73; 95% CI, 0.59-0.89) and mortality (HR, 0.68; 95% CI, CI 0.58-0.81). In time-updated analyses, participants with eGFRdiffcys-cr less than -15 mL/min/1.73 m2 had higher risks of ESKD (SHR, 1.83; 95% CI, 1.10-3.04) and mortality (HR, 3.03; 95% CI, 2.19-4.19) compared with participants with similar eGFRcys and eGFRcr. Conversely, participants with eGFRdiffcys-cr of 15 mL/min/1.73 m2 or greater had lower risks of ESKD (SHR, 0.50; 95% CI, 0.35-0.71) and mortality (HR, 0.58; 95% CI, 0.45-0.75). Longitudinal changes in eGFRdiffcys-cr were associated with mortality risk. Compared with participants who had similar slopes by eGFRcys and eGFRcr, those with smaller eGFRcr declines had an 8-fold increased mortality risk (HR, 8.20; 95% CI, 6.37-10.56), and those with larger apparent declines by eGFRcr had a lower mortality risk (HR, 0.14; 95% CI, 0.08-0.24).ResultsAmong 4956 participants with mean (SD) age of 59.5 (10.5) years, 2152 (43.4%) were Black, 515 (10.4%) were Hispanic, and 2113 (42.6%) were White. There were 2156 (43.5%) women and 2800 (56.5%) men. At baseline, eGFRcys and eGFRcr values differed by more than 15 mL/min/1.73 m2 in one-third of participants (1638 participants [33.1%]). Compared with participants with similar baseline eGFRcys and eGFRcr (eGFRdiffcys-cr -15 to 15 mL/min/1.73 m2), those in whom eGFRcys was substantially lower than eGFRcr (eGFRdiffcys-cr < -15 mL/min/1.73 m2) had a higher risk of mortality (hazard ratio [HR], 1.86; 95% CI, 1.40-2.48) while those with eGFRdiffcys-cr of 15 mL/min/1.73 m2 or greater had lower risks of ESKD (subHR [SHR], 0.73; 95% CI, 0.59-0.89) and mortality (HR, 0.68; 95% CI, CI 0.58-0.81). In time-updated analyses, participants with eGFRdiffcys-cr less than -15 mL/min/1.73 m2 had higher risks of ESKD (SHR, 1.83; 95% CI, 1.10-3.04) and mortality (HR, 3.03; 95% CI, 2.19-4.19) compared with participants with similar eGFRcys and eGFRcr. Conversely, participants with eGFRdiffcys-cr of 15 mL/min/1.73 m2 or greater had lower risks of ESKD (SHR, 0.50; 95% CI, 0.35-0.71) and mortality (HR, 0.58; 95% CI, 0.45-0.75). Longitudinal changes in eGFRdiffcys-cr were associated with mortality risk. Compared with participants who had similar slopes by eGFRcys and eGFRcr, those with smaller eGFRcr declines had an 8-fold increased mortality risk (HR, 8.20; 95% CI, 6.37-10.56), and those with larger apparent declines by eGFRcr had a lower mortality risk (HR, 0.14; 95% CI, 0.08-0.24).These findings suggest that large differences between eGFRcys and eGFRcr were common in persons with CKD. These differences and their changes over time may be informative of ESKD and mortality risks, warranting monitoring of both eGFRcys and eGFRcr in this high-risk population.Conclusions and RelevanceThese findings suggest that large differences between eGFRcys and eGFRcr were common in persons with CKD. These differences and their changes over time may be informative of ESKD and mortality risks, warranting monitoring of both eGFRcys and eGFRcr in this high-risk population. Importance As cystatin C is increasingly adopted to estimate glomerular filtration rate (eGFR), clinicians will encounter patients in whom cystatin C-based eGFR (eGFRcys) and creatinine-based eGFR (eGFRcr) differ widely. The clinical implications of these differences, eGFRdiffcys-cr, are unknown. Objective To evaluate the associations of eGFRdiffcys-crwith end-stage kidney disease (ESKD) and mortality among individuals with chronic kidney disease (CKD). Design, Setting, and Participants This is a prospective cohort study of 4956 individuals with mild to moderate CKD from 7 clinical centers in the United States who enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study between 2003 to 2018. Statistical analyses were completed in December 2021. Exposures eGFRdiffcys-cr(eGFRcys − eGFRcr) was calculated at baseline and annually thereafter for 3 years. Because 15 mL/min/1.73 m2represents a clinically meaningful difference in eGFR that also distinguishes CKD stages, eGFRdiffcys-crwas categorized as: less than −15 mL/min/1.73 m2, −15 to 15 mL/min/1.73 m2, and 15 mL/min/1.73 m2or greater. Main Outcomes and Measures The outcomes of ESKD, defined as initiation of maintenance dialysis or receipt of a kidney transplant, and all-cause mortality were adjudicated from study entry until administrative censoring in 2018. Results Among 4956 participants with mean (SD) age of 59.5 (10.5) years, 2152 (43.4%) were Black, 515 (10.4%) were Hispanic, and 2113 (42.6%) were White. There were 2156 (43.5%) women and 2800 (56.5%) men. At baseline, eGFRcys and eGFRcr values differed by more than 15 mL/min/1.73 m2in one-third of participants (1638 participants [33.1%]). Compared with participants with similar baseline eGFRcys and eGFRcr (eGFRdiffcys-cr−15 to 15 mL/min/1.73 m2), those in whom eGFRcys was substantially lower than eGFRcr (eGFRdiffcys-cr < −15 mL/min/1.73 m2) had a higher risk of mortality (hazard ratio [HR], 1.86; 95% CI, 1.40-2.48) while those with eGFRdiffcys-crof 15 mL/min/1.73 m2or greater had lower risks of ESKD (subHR [SHR], 0.73; 95% CI, 0.59-0.89) and mortality (HR, 0.68; 95% CI, CI 0.58-0.81). In time-updated analyses, participants with eGFRdiffcys-crless than −15 mL/min/1.73 m2had higher risks of ESKD (SHR, 1.83; 95% CI, 1.10-3.04) and mortality (HR, 3.03; 95% CI, 2.19-4.19) compared with participants with similar eGFRcys and eGFRcr. Conversely, participants with eGFRdiffcys-crof 15 mL/min/1.73 m2or greater had lower risks of ESKD (SHR, 0.50; 95% CI, 0.35-0.71) and mortality (HR, 0.58; 95% CI, 0.45-0.75). Longitudinal changes in eGFRdiffcys-crwere associated with mortality risk. Compared with participants who had similar slopes by eGFRcys and eGFRcr, those with smaller eGFRcr declines had an 8-fold increased mortality risk (HR, 8.20; 95% CI, 6.37-10.56), and those with larger apparent declines by eGFRcr had a lower mortality risk (HR, 0.14; 95% CI, 0.08-0.24). Conclusions and Relevance These findings suggest that large differences between eGFRcys and eGFRcr were common in persons with CKD. These differences and their changes over time may be informative of ESKD and mortality risks, warranting monitoring of both eGFRcys and eGFRcr in this high-risk population. This cohort study evaluates associations of differences in glomerular filtration rate estimated by cystatin C vs by creatinine with end-stage kidney disease and mortality. IMPORTANCE: As cystatin C is increasingly adopted to estimate glomerular filtration rate (eGFR), clinicians will encounter patients in whom cystatin C-based eGFR (eGFRcys) and creatinine-based eGFR (eGFRcr) differ widely. The clinical implications of these differences, eGFRdiffcys-cr, are unknown. OBJECTIVE: To evaluate the associations of eGFRdiffcys-cr with end-stage kidney disease (ESKD) and mortality among individuals with chronic kidney disease (CKD). DESIGN, SETTING, AND PARTICIPANTS: This is a prospective cohort study of 4956 individuals with mild to moderate CKD from 7 clinical centers in the United States who enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study between 2003 to 2018. Statistical analyses were completed in December 2021. EXPOSURES: eGFRdiffcys-cr (eGFRcys − eGFRcr) was calculated at baseline and annually thereafter for 3 years. Because 15 mL/min/1.73 m2 represents a clinically meaningful difference in eGFR that also distinguishes CKD stages, eGFRdiffcys-cr was categorized as: less than −15 mL/min/1.73 m2, −15 to 15 mL/min/1.73 m2, and 15 mL/min/1.73 m2 or greater. MAIN OUTCOMES AND MEASURES: The outcomes of ESKD, defined as initiation of maintenance dialysis or receipt of a kidney transplant, and all-cause mortality were adjudicated from study entry until administrative censoring in 2018. RESULTS: Among 4956 participants with mean (SD) age of 59.5 (10.5) years, 2152 (43.4%) were Black, 515 (10.4%) were Hispanic, and 2113 (42.6%) were White. There were 2156 (43.5%) women and 2800 (56.5%) men. At baseline, eGFRcys and eGFRcr values differed by more than 15 mL/min/1.73 m2 in one-third of participants (1638 participants [33.1%]). Compared with participants with similar baseline eGFRcys and eGFRcr (eGFRdiffcys-cr −15 to 15 mL/min/1.73 m2), those in whom eGFRcys was substantially lower than eGFRcr (eGFRdiffcys-cr < −15 mL/min/1.73 m2) had a higher risk of mortality (hazard ratio [HR], 1.86; 95% CI, 1.40-2.48) while those with eGFRdiffcys-cr of 15 mL/min/1.73 m2 or greater had lower risks of ESKD (subHR [SHR], 0.73; 95% CI, 0.59-0.89) and mortality (HR, 0.68; 95% CI, CI 0.58-0.81). In time-updated analyses, participants with eGFRdiffcys-cr less than −15 mL/min/1.73 m2 had higher risks of ESKD (SHR, 1.83; 95% CI, 1.10-3.04) and mortality (HR, 3.03; 95% CI, 2.19-4.19) compared with participants with similar eGFRcys and eGFRcr. Conversely, participants with eGFRdiffcys-cr of 15 mL/min/1.73 m2 or greater had lower risks of ESKD (SHR, 0.50; 95% CI, 0.35-0.71) and mortality (HR, 0.58; 95% CI, 0.45-0.75). Longitudinal changes in eGFRdiffcys-cr were associated with mortality risk. Compared with participants who had similar slopes by eGFRcys and eGFRcr, those with smaller eGFRcr declines had an 8-fold increased mortality risk (HR, 8.20; 95% CI, 6.37-10.56), and those with larger apparent declines by eGFRcr had a lower mortality risk (HR, 0.14; 95% CI, 0.08-0.24). CONCLUSIONS AND RELEVANCE: These findings suggest that large differences between eGFRcys and eGFRcr were common in persons with CKD. These differences and their changes over time may be informative of ESKD and mortality risks, warranting monitoring of both eGFRcys and eGFRcr in this high-risk population. As cystatin C is increasingly adopted to estimate glomerular filtration rate (eGFR), clinicians will encounter patients in whom cystatin C-based eGFR (eGFRcys) and creatinine-based eGFR (eGFRcr) differ widely. The clinical implications of these differences, eGFRdiffcys-cr, are unknown. To evaluate the associations of eGFRdiffcys-cr with end-stage kidney disease (ESKD) and mortality among individuals with chronic kidney disease (CKD). This is a prospective cohort study of 4956 individuals with mild to moderate CKD from 7 clinical centers in the United States who enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study between 2003 to 2018. Statistical analyses were completed in December 2021. eGFRdiffcys-cr (eGFRcys - eGFRcr) was calculated at baseline and annually thereafter for 3 years. Because 15 mL/min/1.73 m2 represents a clinically meaningful difference in eGFR that also distinguishes CKD stages, eGFRdiffcys-cr was categorized as: less than -15 mL/min/1.73 m2, -15 to 15 mL/min/1.73 m2, and 15 mL/min/1.73 m2 or greater. The outcomes of ESKD, defined as initiation of maintenance dialysis or receipt of a kidney transplant, and all-cause mortality were adjudicated from study entry until administrative censoring in 2018. Among 4956 participants with mean (SD) age of 59.5 (10.5) years, 2152 (43.4%) were Black, 515 (10.4%) were Hispanic, and 2113 (42.6%) were White. There were 2156 (43.5%) women and 2800 (56.5%) men. At baseline, eGFRcys and eGFRcr values differed by more than 15 mL/min/1.73 m2 in one-third of participants (1638 participants [33.1%]). Compared with participants with similar baseline eGFRcys and eGFRcr (eGFRdiffcys-cr -15 to 15 mL/min/1.73 m2), those in whom eGFRcys was substantially lower than eGFRcr (eGFRdiffcys-cr < -15 mL/min/1.73 m2) had a higher risk of mortality (hazard ratio [HR], 1.86; 95% CI, 1.40-2.48) while those with eGFRdiffcys-cr of 15 mL/min/1.73 m2 or greater had lower risks of ESKD (subHR [SHR], 0.73; 95% CI, 0.59-0.89) and mortality (HR, 0.68; 95% CI, CI 0.58-0.81). In time-updated analyses, participants with eGFRdiffcys-cr less than -15 mL/min/1.73 m2 had higher risks of ESKD (SHR, 1.83; 95% CI, 1.10-3.04) and mortality (HR, 3.03; 95% CI, 2.19-4.19) compared with participants with similar eGFRcys and eGFRcr. Conversely, participants with eGFRdiffcys-cr of 15 mL/min/1.73 m2 or greater had lower risks of ESKD (SHR, 0.50; 95% CI, 0.35-0.71) and mortality (HR, 0.58; 95% CI, 0.45-0.75). Longitudinal changes in eGFRdiffcys-cr were associated with mortality risk. Compared with participants who had similar slopes by eGFRcys and eGFRcr, those with smaller eGFRcr declines had an 8-fold increased mortality risk (HR, 8.20; 95% CI, 6.37-10.56), and those with larger apparent declines by eGFRcr had a lower mortality risk (HR, 0.14; 95% CI, 0.08-0.24). These findings suggest that large differences between eGFRcys and eGFRcr were common in persons with CKD. These differences and their changes over time may be informative of ESKD and mortality risks, warranting monitoring of both eGFRcys and eGFRcr in this high-risk population. |
| Author | Scherzer, Rebecca Hsu, Chi-yuan Chen, Debbie C Estrella, Michelle M Bauer, Scott R Ix, Joachim H Shlipak, Michael G Rifkin, Dena E Potok, O. Alison Muiru, Anthony N |
| AuthorAffiliation | 4 Department Epidemiology and Biostatistics, University of California, San Francisco 1 Division of Nephrology, Department of Medicine, University of California, San Francisco 7 Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California 5 Division of General Internal Medicine, University of California, San Francisco 3 Department of Medicine, San Francisco VA Medical Center, San Francisco, California 6 Division of Nephrology and Hypertension, Department of Medicine, University of California, San Diego 2 Kidney Health Research Collaborative, San Francisco VA Health Care System & University of California, San Francisco 8 Division of Nephrology, Department of Medicine, San Francisco VA Medical Center, San Francisco, California |
| AuthorAffiliation_xml | – name: 6 Division of Nephrology and Hypertension, Department of Medicine, University of California, San Diego – name: 8 Division of Nephrology, Department of Medicine, San Francisco VA Medical Center, San Francisco, California – name: 7 Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, California – name: 5 Division of General Internal Medicine, University of California, San Francisco – name: 1 Division of Nephrology, Department of Medicine, University of California, San Francisco – name: 4 Department Epidemiology and Biostatistics, University of California, San Francisco – name: 3 Department of Medicine, San Francisco VA Medical Center, San Francisco, California – name: 2 Kidney Health Research Collaborative, San Francisco VA Health Care System & University of California, San Francisco |
| Author_xml | – sequence: 1 givenname: Debbie C surname: Chen fullname: Chen, Debbie C – sequence: 2 givenname: Michael G surname: Shlipak fullname: Shlipak, Michael G – sequence: 3 givenname: Rebecca surname: Scherzer fullname: Scherzer, Rebecca – sequence: 4 givenname: Scott R surname: Bauer fullname: Bauer, Scott R – sequence: 5 givenname: O. Alison surname: Potok fullname: Potok, O. Alison – sequence: 6 givenname: Dena E surname: Rifkin fullname: Rifkin, Dena E – sequence: 7 givenname: Joachim H surname: Ix fullname: Ix, Joachim H – sequence: 8 givenname: Anthony N surname: Muiru fullname: Muiru, Anthony N – sequence: 9 givenname: Chi-yuan surname: Hsu fullname: Hsu, Chi-yuan – sequence: 10 givenname: Michelle M surname: Estrella fullname: Estrella, Michelle M |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35175342$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUsFu1DAQjVARLaU_wAFZcOGSxXbi2OaAqMK2VBQhIThbju0UL1l7sZ1F-RM-F2e3rcqeONmeee_NjOc9LY6cd6YoXiK4QBCiNyu5ls6k3z789BvjFhhitKgZr-Gj4gQTWpcVg-Towf24OItxBSHEEFW8IU-K44ogSqoanxR_zmP0yspkvQO-B1cuBWmdtlurRzmAD7bvTTBOGWAdWMZk1zIZDS4HvzZhHGQAF3bInJ3A15wD3QTaYHLAWWfANoJ2iml-ghZIp8HS6TIHbgz4ZLUzU64RjYxml_zsQ5KDTdOz4nEvh2jObs_T4vvF8lv7sbz-cnnVnl-XsqZVKjkkdYMaBWvYU8Y6ijHluFO8Q8qoroOorpqONbDuuao7qYgmVDMqqSaMaFadFu_2upuxWxutzPwBg9iEPGiYhJdW_Jtx9oe48VvBGCG44lng9a1A8L9GE5NY26jMMOQ1-TEK3GDOCMesydBXB9CVH4PL42VUQxpMEZ87evGwo_tW7paWAe_3ABV8jMH0Qtm0W8C8u0EgKGariAOriNkqYmeVLPH2QOKuyn-Rn-_JGXLPw5RxVMHqL65g1gQ |
| CitedBy_id | crossref_primary_10_1007_s11255_024_04119_0 crossref_primary_10_2215_CJN_0000000000000217 crossref_primary_10_1002_jcsm_13469 crossref_primary_10_1016_j_clnesp_2025_07_1112 crossref_primary_10_1093_ckj_sfaf208 crossref_primary_10_1001_jamanetworkopen_2023_21715 crossref_primary_10_3389_fmed_2024_1477343 crossref_primary_10_1097_LVT_0000000000000439 crossref_primary_10_1093_jalm_jfad022 crossref_primary_10_1111_joim_20035 crossref_primary_10_1053_j_jrn_2024_12_007 crossref_primary_10_1093_ckj_sfaf003 crossref_primary_10_1093_ndt_gfad234 crossref_primary_10_1186_s12986_024_00870_4 crossref_primary_10_1016_j_clinbiochem_2024_110801 crossref_primary_10_1111_eci_14278 crossref_primary_10_1186_s40001_025_02988_4 crossref_primary_10_1016_j_diabres_2025_112419 crossref_primary_10_1161_JAHA_124_039185 crossref_primary_10_2337_dc23_2364 crossref_primary_10_2147_JIR_S496590 crossref_primary_10_1080_0886022X_2025_2466824 crossref_primary_10_1093_clinchem_hvaf079 crossref_primary_10_1177_08971900241262381 crossref_primary_10_1053_j_akdh_2024_07_004 crossref_primary_10_1016_j_ekir_2025_04_003 crossref_primary_10_1016_j_ekir_2025_08_029 crossref_primary_10_1136_bmj_2022_074216 crossref_primary_10_1016_j_jad_2024_09_169 crossref_primary_10_1016_j_xkme_2024_100806 crossref_primary_10_1093_ndt_gfae011 crossref_primary_10_1016_j_clinbiochem_2024_110853 crossref_primary_10_1053_j_ajkd_2022_05_011 crossref_primary_10_1053_j_ajkd_2023_11_004 crossref_primary_10_1038_s41598_024_69623_w crossref_primary_10_1016_j_heliyon_2024_e39274 crossref_primary_10_1016_j_xkme_2023_100710 crossref_primary_10_1177_23969873231173282 crossref_primary_10_1007_s12291_023_01125_4 crossref_primary_10_1016_j_xkme_2024_100796 crossref_primary_10_1093_eurheartj_ehad210 crossref_primary_10_1097_MNH_0000000000000980 crossref_primary_10_1080_17582024_2025_2554224 crossref_primary_10_1093_clinchem_hvaf063 crossref_primary_10_1016_j_cca_2025_120450 crossref_primary_10_1080_0886022X_2025_2482127 crossref_primary_10_1097_QAI_0000000000003555 crossref_primary_10_7759_cureus_63296 crossref_primary_10_1038_s41598_023_31048_2 crossref_primary_10_1002_jac5_1870 crossref_primary_10_1053_j_ajkd_2025_03_018 crossref_primary_10_1681_ASN_0000000670 crossref_primary_10_2147_CIA_S447042 crossref_primary_10_1681_ASN_0000000000000128 crossref_primary_10_3390_ijms25073678 crossref_primary_10_1080_00365513_2025_2546320 crossref_primary_10_34067_KID_0003202022 crossref_primary_10_1053_j_ajkd_2023_04_002 crossref_primary_10_1016_j_ejim_2025_03_008 crossref_primary_10_1002_jcsm_70011 crossref_primary_10_1093_jalm_jfae103 crossref_primary_10_1186_s12916_022_02539_2 crossref_primary_10_1053_j_ajkd_2023_03_005 crossref_primary_10_1016_j_thromres_2024_109097 crossref_primary_10_1161_JAHA_124_040630 |
| Cites_doi | 10.7326/0003-4819-145-4-200608150-00003 10.1038/ki.2008.638 10.1097/01.ASN.0000070149.78399.CE 10.1053/j.ajkd.2013.05.022 10.2215/CJN.02870313 10.1053/j.ajkd.2011.05.010 10.1681/ASN.2005050545 10.7326/0003-4819-147-1-200707030-00004 10.1056/NEJMoa2103753 10.1111/biom.2011.67.issue-3 10.7326/0003-4819-142-7-200504050-00008 10.1186/s12882-020-01932-4 10.1097/MNH.0000000000000638 10.1080/01621459.1999.10474144 10.1681/ASN.2006050493 10.1056/NEJMoa1214234 10.1007/BF03347201 10.1111/j.1523-1755.2004.00517.x 10.1681/ASN.2010050483 10.1053/j.ajkd.2020.05.018 10.7326/0003-4819-150-9-200905050-00006 10.1056/NEJMoa1114248 10.1186/s12882-017-0759-3 10.2307/2533118 10.1053/j.ajkd.2016.08.034 10.1053/j.ajkd.2020.05.017 10.1046/j.1523-1755.2003.00925.x 10.1038/ki.2010.536 10.1097/01.ASN.0000057856.88335.DD 10.1001/jama.2011.468 10.1056/NEJMoa2102953 10.18637/jss.v084.i12 10.2215/CJN.00070109 10.1016/S0140-6736(10)60674-5 10.2337/dc13-1770 10.1056/NEJMoa041031 10.1053/j.ajkd.2017.09.015 10.1111/jgs.12413 |
| ContentType | Journal Article |
| Copyright | 2022. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright 2022 Chen DC et al. . |
| Copyright_xml | – notice: 2022. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright 2022 Chen DC et al. . |
| DBID | ZGVWO AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1001/jamanetworkopen.2021.48940 |
| DatabaseName | JAMA Network (Open Access) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest One Health & Nursing ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: ZGVWO name: JAMA Network (Open Access) url: https://jamanetwork.com sourceTypes: Publisher – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | Difference in Estimated Glomerular Filtration Rate by Creatinine vs Cystatin C and End-stage Kidney Disease and Mortality |
| EISSN | 2574-3805 |
| ExternalDocumentID | PMC8855239 35175342 10_1001_jamanetworkopen_2021_48940 2789130 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Observational Study Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIDDK NIH HHS grantid: K12 DK111028 – fundername: NIDDK NIH HHS grantid: K23 DK119562 – fundername: NIA NIH HHS grantid: R03 AG067937 – fundername: NIDDK NIH HHS grantid: F32 DK130543 – fundername: NIDDK NIH HHS grantid: K23 DK128604 – fundername: NIA NIH HHS grantid: P30 AG044281 – fundername: NIDDK NIH HHS grantid: T32 DK007219 – fundername: NIDDK NIH HHS grantid: U01 DK060984 – fundername: NIA NIH HHS grantid: K76 AG074903 |
| GroupedDBID | ZGVWO 0R~ 53G 7X7 8FI 8FJ AAYXX ABUWG ADBBV ADPDF AFFHD AFKRA ALMA_UNASSIGNED_HOLDINGS AMJDE BCNDV BENPR CCPQU CITATION EBS EMOBN FYUFA GROUPED_DOAJ H13 HMCUK OK1 OVD OVEED PHGZM PHGZT PIMPY RAJ TEORI UKHRP W2D ALIPV CGR CUY CVF ECM EIF M~E NPM 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-a473t-9054616c040f788b722792bc9b1cecbb01436b8604f9c4bac5d57d87a7d585d83 |
| IEDL.DBID | PIMPY |
| ISICitedReferencesCount | 68 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000757513900006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2574-3805 |
| IngestDate | Tue Nov 04 01:49:43 EST 2025 Thu Oct 02 10:09:00 EDT 2025 Tue Oct 07 06:48:19 EDT 2025 Thu Jan 02 22:52:27 EST 2025 Tue Nov 18 22:15:59 EST 2025 Sat Nov 29 06:31:44 EST 2025 Fri Jul 05 02:02:26 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Language | English |
| License | This is an open access article distributed under the terms of the CC-BY License. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a473t-9054616c040f788b722792bc9b1cecbb01436b8604f9c4bac5d57d87a7d585d83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.proquest.com/publiccontent/docview/2665627198?pq-origsite=%requestingapplication% |
| PMID | 35175342 |
| PQID | 2665627198 |
| PQPubID | 5319538 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8855239 proquest_miscellaneous_2629859286 proquest_journals_2665627198 pubmed_primary_35175342 crossref_citationtrail_10_1001_jamanetworkopen_2021_48940 crossref_primary_10_1001_jamanetworkopen_2021_48940 ama_primary_2789130 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-02-01 |
| PublicationDateYYYYMMDD | 2022-02-01 |
| PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Chicago |
| PublicationTitle | JAMA Network Open |
| PublicationTitleAlternate | JAMA Netw Open |
| PublicationYear | 2022 |
| Publisher | American Medical Association |
| Publisher_xml | – name: American Medical Association |
| References | van der Velde (zoi211342r4) 2011; 79 Lash (zoi211342r21) 2009; 4 Rizopoulos (zoi211342r28) 2011; 67 Manetti (zoi211342r41) 2005; 28 Fischer (zoi211342r22) 2011; 58 Delgado (zoi211342r15) 2021; S0272-6386 Legrand (zoi211342r18) 2017; 18 Shlipak (zoi211342r34) 2006; 145 zoi211342r1 Shlipak (zoi211342r32) 2013; 369 Go (zoi211342r2) 2004; 351 Kang (zoi211342r19) 2020; 21 Potok (zoi211342r6) 2020; 76 Knight (zoi211342r33) 2004; 65 Peralta (zoi211342r31) 2011; 305 Fine (zoi211342r24) 1999; 94 Peralta (zoi211342r38) 2011; 22 Nair (zoi211342r8) 2014; 37 Hart (zoi211342r9) 2013; 61 Hsu (zoi211342r14) 2021; 385 Garcia-Hernandez (zoi211342r26) 2018; 84 Ballew (zoi211342r13) 2017; 69 Sarnak (zoi211342r35) 2005; 142 Ebert (zoi211342r39) 2020; 29 Dalrymple (zoi211342r11) 2013; 8 Wulfsohn (zoi211342r27) 1997; 53 Fricker (zoi211342r42) 2003; 63 Peralta (zoi211342r30) 2006; 17 Matsushita (zoi211342r3) 2010; 375 Stevens (zoi211342r16) 2009; 75 Ensrud (zoi211342r10) 2014; 63 Inker (zoi211342r7) 2021; 385 Stevens (zoi211342r17) 2013; 3 zoi211342r40 Potok (zoi211342r5) 2020; 76 Beddhu (zoi211342r12) 2003; 14 Feldman (zoi211342r20) 2003; 14 Levey (zoi211342r29) 2009; 150 Menon (zoi211342r37) 2007; 147 Inker (zoi211342r23) 2012; 367 Shlipak (zoi211342r36) 2006; 17 Ku (zoi211342r25) 2018; 71 |
| References_xml | – volume: 145 start-page: 237 issue: 4 year: 2006 ident: zoi211342r34 article-title: Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. publication-title: Ann Intern Med doi: 10.7326/0003-4819-145-4-200608150-00003 – volume: 75 start-page: 652 issue: 6 year: 2009 ident: zoi211342r16 article-title: Factors other than glomerular filtration rate affect serum cystatin C levels. publication-title: Kidney Int doi: 10.1038/ki.2008.638 – volume: 14 start-page: S148 issue: 7 year: 2003 ident: zoi211342r20 article-title: The Chronic Renal Insufficiency Cohort (CRIC) Study: design and methods. publication-title: J Am Soc Nephrol doi: 10.1097/01.ASN.0000070149.78399.CE – volume: 63 start-page: 31 issue: 1 year: 2014 ident: zoi211342r10 article-title: Estimated GFR and risk of hip fracture in older men: comparison of associations using cystatin C and creatinine. publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2013.05.022 – volume: 8 start-page: 2091 issue: 12 year: 2013 ident: zoi211342r11 article-title: Kidney function and prevalent and incident frailty. publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.02870313 – volume: 58 start-page: 214 issue: 2 year: 2011 ident: zoi211342r22 article-title: CKD in Hispanics: baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies. publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2011.05.010 – volume: 17 start-page: 254 issue: 1 year: 2006 ident: zoi211342r36 article-title: Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2005050545 – volume: 147 start-page: 19 issue: 1 year: 2007 ident: zoi211342r37 article-title: Cystatin C as a risk factor for outcomes in chronic kidney disease. publication-title: Ann Intern Med doi: 10.7326/0003-4819-147-1-200707030-00004 – volume: 385 start-page: 1750 issue: 19 year: 2021 ident: zoi211342r14 article-title: Race, genetic ancestry, and estimating kidney function in CKD. publication-title: N Engl J Med doi: 10.1056/NEJMoa2103753 – volume: 67 start-page: 819 issue: 3 year: 2011 ident: zoi211342r28 article-title: Dynamic predictions and prospective accuracy in joint models for longitudinal and time-to-event data. publication-title: Biometrics doi: 10.1111/biom.2011.67.issue-3 – volume: 142 start-page: 497 issue: 7 year: 2005 ident: zoi211342r35 article-title: Cystatin C concentration as a risk factor for heart failure in older adults. publication-title: Ann Intern Med doi: 10.7326/0003-4819-142-7-200504050-00008 – volume: 21 start-page: 280 issue: 1 year: 2020 ident: zoi211342r19 article-title: Discrepant glomerular filtration rate trends from creatinine and cystatin C in patients with chronic kidney disease: results from the KNOW-CKD cohort. publication-title: BMC Nephrol doi: 10.1186/s12882-020-01932-4 – volume: 29 start-page: 591 issue: 6 year: 2020 ident: zoi211342r39 article-title: Cystatin C is ready for clinical use. publication-title: Curr Opin Nephrol Hypertens doi: 10.1097/MNH.0000000000000638 – volume: 94 start-page: 496 issue: 446 year: 1999 ident: zoi211342r24 article-title: A proportional hazards model for the subdistribution of a competing risk. publication-title: J Am Stat Assoc doi: 10.1080/01621459.1999.10474144 – volume: 17 start-page: 3491 issue: 12 year: 2006 ident: zoi211342r30 article-title: African ancestry, socioeconomic status, and kidney function in elderly African Americans: a genetic admixture analysis. publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2006050493 – volume: 369 start-page: 932 issue: 10 year: 2013 ident: zoi211342r32 article-title: Cystatin C versus creatinine in determining risk based on kidney function. publication-title: N Engl J Med doi: 10.1056/NEJMoa1214234 – volume: 28 start-page: 346 issue: 4 year: 2005 ident: zoi211342r41 article-title: Thyroid function differently affects serum cystatin C and creatinine concentrations. publication-title: J Endocrinol Invest doi: 10.1007/BF03347201 – volume: 65 start-page: 1416 issue: 4 year: 2004 ident: zoi211342r33 article-title: Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. publication-title: Kidney Int doi: 10.1111/j.1523-1755.2004.00517.x – volume: 22 start-page: 147 issue: 1 year: 2011 ident: zoi211342r38 article-title: Cystatin C identifies chronic kidney disease patients at higher risk for complications. publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2010050483 – volume: 76 start-page: 896 issue: 6 year: 2020 ident: zoi211342r5 article-title: The difference between cystatin C- and creatinine-based estimated GFR and incident frailty: an analysis of the Cardiovascular Health Study (CHS). publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2020.05.018 – volume: 150 start-page: 604 issue: 9 year: 2009 ident: zoi211342r29 article-title: A new equation to estimate glomerular filtration rate. publication-title: Ann Intern Med doi: 10.7326/0003-4819-150-9-200905050-00006 – volume: 367 start-page: 20 issue: 1 year: 2012 ident: zoi211342r23 article-title: Estimating glomerular filtration rate from serum creatinine and cystatin C. publication-title: N Engl J Med doi: 10.1056/NEJMoa1114248 – volume: 18 start-page: 350 issue: 1 year: 2017 ident: zoi211342r18 article-title: Prevalence and determinants of differences in cystatin C and creatinine-based estimated glomerular filtration rate in community-dwelling older adults: a cross-sectional study. publication-title: BMC Nephrol doi: 10.1186/s12882-017-0759-3 – volume: 53 start-page: 330 issue: 1 year: 1997 ident: zoi211342r27 article-title: A joint model for survival and longitudinal data measured with error. publication-title: Biometrics doi: 10.2307/2533118 – volume: 69 start-page: 228 issue: 2 year: 2017 ident: zoi211342r13 article-title: Frailty, kidney function, and polypharmacy: the Atherosclerosis Risk in Communities (ARIC) Study. publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2016.08.034 – ident: zoi211342r1 – volume: 76 start-page: 765 issue: 6 year: 2020 ident: zoi211342r6 article-title: The difference between cystatin C- and creatinine-based estimated GFR and associations with frailty and adverse outcomes: a cohort analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2020.05.017 – volume: 63 start-page: 1944 issue: 5 year: 2003 ident: zoi211342r42 article-title: Impact of thyroid dysfunction on serum cystatin C. publication-title: Kidney Int doi: 10.1046/j.1523-1755.2003.00925.x – volume: 79 start-page: 1341 issue: 12 year: 2011 ident: zoi211342r4 article-title: Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality: a collaborative meta-analysis of high-risk population cohorts. publication-title: Kidney Int doi: 10.1038/ki.2010.536 – ident: zoi211342r40 – volume: 14 start-page: 1000 issue: 4 year: 2003 ident: zoi211342r12 article-title: Creatinine production, nutrition, and glomerular filtration rate estimation. publication-title: J Am Soc Nephrol doi: 10.1097/01.ASN.0000057856.88335.DD – volume: 305 start-page: 1545 issue: 15 year: 2011 ident: zoi211342r31 article-title: Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. publication-title: JAMA doi: 10.1001/jama.2011.468 – volume: S0272-6386 issue: 21 year: 2021 ident: zoi211342r15 article-title: A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease. publication-title: Am J Kidney Dis – volume: 385 start-page: 1737 issue: 19 year: 2021 ident: zoi211342r7 article-title: New creatinine- and cystatin C-based equations to estimate GFR without race. publication-title: N Engl J Med doi: 10.1056/NEJMoa2102953 – volume: 84 start-page: 1 issue: 12 year: 2018 ident: zoi211342r26 article-title: %JM: a SAS macro to fit jointly generalized mixed models for longitudinal data and time-to-event responses. publication-title: J Stat Softw doi: 10.18637/jss.v084.i12 – volume: 4 start-page: 1302 issue: 8 year: 2009 ident: zoi211342r21 article-title: Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. publication-title: Clin J Am Soc Nephrol doi: 10.2215/CJN.00070109 – volume: 375 start-page: 2073 issue: 9731 year: 2010 ident: zoi211342r3 article-title: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. publication-title: Lancet doi: 10.1016/S0140-6736(10)60674-5 – volume: 3 start-page: 1 issue: 1 year: 2013 ident: zoi211342r17 article-title: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. publication-title: Kidney Int Suppl – volume: 37 start-page: 483 issue: 2 year: 2014 ident: zoi211342r8 article-title: Effect of a cooked meat meal on serum creatinine and estimated glomerular filtration rate in diabetes-related kidney disease. publication-title: Diabetes Care doi: 10.2337/dc13-1770 – volume: 351 start-page: 1296 issue: 13 year: 2004 ident: zoi211342r2 article-title: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. publication-title: N Engl J Med doi: 10.1056/NEJMoa041031 – volume: 71 start-page: 657 issue: 5 year: 2018 ident: zoi211342r25 article-title: Longitudinal weight change during CKD progression and its association with subsequent mortality. publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2017.09.015 – volume: 61 start-page: 1530 issue: 9 year: 2013 ident: zoi211342r9 article-title: Cystatin C and frailty in older men. publication-title: J Am Geriatr Soc doi: 10.1111/jgs.12413 |
| SSID | ssj0002013965 |
| Score | 2.4474947 |
| Snippet | IMPORTANCE: As cystatin C is increasingly adopted to estimate glomerular filtration rate (eGFR), clinicians will encounter patients in whom cystatin C-based... As cystatin C is increasingly adopted to estimate glomerular filtration rate (eGFR), clinicians will encounter patients in whom cystatin C-based eGFR (eGFRcys)... Importance As cystatin C is increasingly adopted to estimate glomerular filtration rate (eGFR), clinicians will encounter patients in whom cystatin C-based... This cohort study evaluates associations of differences in glomerular filtration rate estimated by cystatin C vs by creatinine with end-stage kidney disease... |
| SourceID | pubmedcentral proquest pubmed crossref ama |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e2148940 |
| SubjectTerms | Aged Creatinine Creatinine - blood Cystatin C - blood Female Glomerular Filtration Rate - physiology Humans Kidney diseases Kidney Failure, Chronic - epidemiology Kidney Failure, Chronic - mortality Kidney Failure, Chronic - physiopathology Kidney Failure, Chronic - therapy Male Middle Aged Mortality Nephrology Online Only Original Investigation Renal Dialysis Risk Factors |
| SummonAdditionalLinks | – databaseName: JAMA Network (Open Access) dbid: ZGVWO link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxELZQyoEL78dCQUbiuijrtdf2EaVJWwEFISgVl5WfZaXgoCStlH_Cz-3Y-1BSEEJc1zv2yjOz_kae-QahV1YyJTwf514Sk9NC8VwV1EOoUirmaWF16tZw-o6fnIizM_lxqyjs-g1-yw8U2pTo2FAKQjpSvKZCUgjU9whnjI3Q3rfD068fBk7RvwltM6r2p9Bv0PJ6huTWkTO7838fexfd7iAmftPaxD10w4UH6NeWHvDC4-OQmkP01Vj4oGuUYhxuAp6C4wOUdRYfzhc_3DLmquJZM-84dvEnGMN6gycJcgZAqvhyhSebWJ4E4hOsgsXTYHN4cO7w28YGt4E10mVQGnyfYD-EAA_Rl9n08-Qo77oy5Irycp1LAHlVURnwfg_xs-aJg1AbqQvjjNaRMLDSohpTLw3VyjDLuBVccQuhiRXlIzQKi-CeICzGAB6V46X0sbQdIk3vDBGFN6KCf7DM0H3Yz_pny7tRx6JdOHIzJHvd1aYjMo9bNq9bCmYIaHa1UEct1EkLGSoH2X7af5Ha702k7lx8VQOyAezICyky9HIYBueMNy4w0eIivkOkYJKIKkOPW4sali1ZJEmlJEN8x9aGFyLx9-5IaL4nAnAhGCOlfPrH7XmGbpFYopEyy_fRaL28cM_RTXO5blbLF52rXAG2SRxK priority: 102 providerName: American Medical Association |
| Title | Association of Intraindividual Difference in Estimated Glomerular Filtration Rate by Creatinine vs Cystatin C and End-stage Kidney Disease and Mortality |
| URI | http://dx.doi.org/10.1001/jamanetworkopen.2021.48940 https://www.ncbi.nlm.nih.gov/pubmed/35175342 https://www.proquest.com/docview/2665627198 https://www.proquest.com/docview/2629859286 https://pubmed.ncbi.nlm.nih.gov/PMC8855239 |
| Volume | 5 |
| WOSCitedRecordID | wos000757513900006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2574-3805 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002013965 issn: 2574-3805 databaseCode: DOA dateStart: 20180101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2574-3805 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002013965 issn: 2574-3805 databaseCode: 7X7 dateStart: 20180101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2574-3805 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002013965 issn: 2574-3805 databaseCode: BENPR dateStart: 20180101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2574-3805 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002013965 issn: 2574-3805 databaseCode: PIMPY dateStart: 20180101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED-xlgdeYHyNwKiMxGtY82n7CUHXjglWqglG4SVKbAciFWe03aT-J_y5nB0nW0FCPPDSSHWctLnL3f3su98BPJc8yVlJh37JQ-HHQU79PIhLhCpRnpRxIAvbreHsHZ1O2XzOZ648euXSKlubaA11w_Zs8rbRCB_IWpgV8wN0K-i4KSLml-c_fNNDyuy1uoYaO9A3xFusB_3Z8cnsc7fmEpp4J0067tGGfEg3-damWxXixTB4ETNu1kKumFdbb_VHCPp7JuU11zS583__1C7cdiEqedXo1F24ofR9-HlNjqQuybG2zSXaai5y6BqtCEUqTcZoODAUVpIcLervamlyXcmkWjiOXnKKY6TYkJENWTVGuuRyRUYbU96E00ck15KMtfTxi6-KvK2kVhu8h91MsoMnFjYghHgAHyfjD6M3vuvq4OcxjdY-xyAxDVKB1qNE_F1Qy2FYCF4EQomiMISDacHSYVxyERe5SGRCJaM5lQhtJIseQk_XWj0CwoYYfOaKRrw0pfGIVEslQhaUgqVow7kH91CG2XnD25GZol902R7wVqaZcETo5pEtsobCGQHRtlZkRisyqxUeRN3c9rL_Mmu_FX_mTMQqu5K2B8-6YXy5zY4NXqi-MOeEnCU8ZKkHe42mdbeNEkOyGoce0C0d7E4wxOHbI7r6ZgnEGUuSMOKP__6znsCt0NR62BT1feitlxfqKdwUl-tqtRzADp1T-8kG0H89ns5OB3ZBY-DeOjx-OTr79P4Xib9Akg |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB6VgkQvvB8LBYwEx4Ws92H7gBBKExoljRAqKLftru2lKwVvSdKi_BN-Bb-RsffRBiTEpQeu8dobeT-Pv7FnvgF4oUSc8YL1_EJQ6UdBxvwsiAp0VcIsLqJA5a5aw-cJm075bCY-bMHPNhfGhlW2NtEZalVJe0b-GjcS3KoZ-shvT775tmqUvV1tS2jUsBjr9Xd02ZZvRnv4fV9SOhwc9vf9pqqAn0UsXPkCSUoSJBLRW6D_lzOnoZdLkQdSyzy3gndJzpNeVAgZ5ZmMVcwUZxlTSK0VD3HcK3AV7TizIWRsxrozHWr5VBJ32qa1uJGp47ltNSz0R2nwKuLCnrWcK7u2u-EfFPf3SM0LW9_w5v82abfgRkOyybt6VdyGLW3uwo8LSCRVQUbGlcdo89HIXlMqRmpSGjJA04dkXivyfl591QsbrUuG5bxRGSYfsY3ka9J3pNsgVydnS9Jf2wQt7N4nmVFkYJSPP3zRZFwqo9f4Dncd5hoPnOODTtA9-HQpk3Eftk1l9EMgvIf0OdMsFIVN7kdfu9CS8qCQPMFdSHhwB1GSntTKI6lNW0bS4YFoUZPKRsrdTtk8rUWo0aXbxF1qcZc63HkQdn3bYf-l124LsLQxcsv0HF0ePO-a0TzZOyccqDq1z1DBY0F54sGDGsvda8PYysRG1AO2gfLuASt9vtliymMngc55HNNQPPr733oG1_cPDybpZDQdP4YdajNXXMD9LmyvFqf6CVyTZ6tyuXjq1jGBo8teA78Aw0OJFw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Association+of+Intraindividual+Difference+in+Estimated+Glomerular+Filtration+Rate+by+Creatinine+vs+Cystatin+C+and+End-stage+Kidney+Disease+and+Mortality&rft.jtitle=JAMA+network+open&rft.au=Chen%2C+Debbie+C&rft.au=Shlipak%2C+Michael+G&rft.au=Scherzer%2C+Rebecca&rft.au=Bauer%2C+Scott+R&rft.date=2022-02-01&rft.issn=2574-3805&rft.eissn=2574-3805&rft.volume=5&rft.issue=2&rft.spage=e2148940&rft_id=info:doi/10.1001%2Fjamanetworkopen.2021.48940&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2574-3805&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2574-3805&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2574-3805&client=summon |